References
- DrummondMSculpherMTorranceGO’BrienBStoddartGMethods for the Economic Evaluation of Health Care Programmes3rd edOxford, UKOxford University Press2005
- HTAGlossary.netHealth Technology Assessment (HTA) Available from: http://htaglossary.net/health+technology+assessment+(HTA)Accessed December 17, 2014
- SimoensSHow to assess the value of medicines?Front Pharmacol2010111521607066
- OrphanetAbout orphan drugs Available from: http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=ENAccessed February 5, 2015
- DrummondMChallenges in the economic evaluation of orphan drugsEurohealth20081421617
- Hughes-WilsonWPalmaASchuurmanASimoensSPaying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Orphanet J Rare Dis201277423013790
- NICEAppraising life-extending, end of life treatments 2009 Available from: http://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2Accessed December 4, 2014
- NICEGuide to the methods of technology appraisal 2013 Available from: http://www.nice.org.uk/article/pmg9/chapter/forewordAccessed December 10, 2014
- GeorgeBHarrisAMitchellACost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996)Pharmacoeconomics200119111103110911735677
- International Society for Pharmacoeconomics and Outcomes ResearchISPOR Global Health Care Systems Road Map Available from: http://www.ispor.org/HTARoadMaps/Default.aspAccessed December 4, 2014
- SMCCarglumic acid 200mg dispersible tablets (Carbaglu) No 299//06 Available from: http://www.scottishmedicines.org.uk/files/carglumic_acid_200mg_Carbaglu_299_06.pdfAccessed February 10, 2015
- PBACEverolimus, tablets, 2.5 mg, 5 mg and 10 mg, Afinitor® – April 2013 Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-04/everolimusAccessed February 10, 2015
- CADTHCEDAC final recommendation for sunitinib (Sutent™) Available from: http://www.cadth.ca/media/cdr/complete/cdr_complete_Sutent_March-28-07.pdfAccessed February 10, 2015
- DakinHADevlinNJOdeyemiIA“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-makingHealth Policy20067735236716213624
- Department of HealthA new value-based approach to the pricing of branded medicines – a consultation Available from: http://www.dhsspsni.gov.uk/medicineconsultation.pdfAccessed December 4, 2014
- Nature News BlogUK backs away from ‘value-based pricing’ for drugs Available from: http://blogs.Nature.com/news/2013/11/uk-backs-away-from-value-based-pricing-for-drugs.htmlAccessed June 24, 2015
- NICEDecisionSupportUnitMinersACairnsJWaillooADepartment of Health proposals for including wider societal benefits into value based pricing: a description and critique Available from: http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/DSU-Wider-Societal-Benefits-Briefing-Paper.pdfAccessed June 24, 2015
- LinleyWGHughesDASocietal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great BritainHealth Econ20132294896422961976
- VegterSRozenbaumMHPostemaRTolleyKPostmaMJReview of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluationsClin Ther20103291651166120974323
- NICEGuide to the processes of technology appraisal 2014 Available from: http://www.nice.org.uk/article/pmg19/chapter/AcknowledgementsAccessed December 4, 2014
- DevlinNParkinDDoes NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Econ20041343745215127424
- SMCScottish Medicines Consortium: What we do (remit) Available from: http://www.scottishmedicines.org.uk/About_SMC/What_we_do/RemitAccessed December 4, 2014
- ClementFMHarrisALiJJYongKLeeKMMannsBJUsing effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and CanadaJAMA20093021437144319809025
- CADTHProcedure for the CADTH Common Drug Review Available from: http://www.cadth.ca/media/cdr/process/CDR_Procedure.pdfAccessed December 4, 2014
- HarrisAHHillSRChinGLiJJWalkomEThe role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004Med Decis Making200828571372218378939
- MauskopfJChirilaCMasaquelCRelationship between financial impact and coverage of drugs in AustraliaInt J Technol Assess Health Care2013299210023217275
- ChimLKellyPJSalkeldGStocklerMRAre cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?Pharmacoeconomics20102846347520465315